Neuren Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Neuren Pharmaceuticals has a total shareholder equity of A$219.2M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$228.2M and A$9.0M respectively. Neuren Pharmaceuticals's EBIT is A$155.2M making its interest coverage ratio -14.3. It has cash and short-term investments of A$213.2M.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	-14.3x
Cash	AU$213.17m
Equity	AU$219.15m
Total liabilities	AU$9.00m
Total assets	AU$228.15m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: NURP.F's short term assets (A$228.0M) exceed its short term liabilities (A$9.0M).

Long Term Liabilities: NURP.F's short term assets (A$228.0M) exceed its long term liabilities (A$29.0K).

Debt to Equity History and Analysis

Debt Level: NURP.F is debt free.

Reducing Debt: NURP.F has not had any debt for past 5 years.

Debt Coverage: NURP.F has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NURP.F has no debt, therefore coverage of interest payments is not a concern.

Neuren Pharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Recent updates

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Neuren Pharmaceuticals Reports Rett Syndrome New Drug Application Accepted for Priority Review by US Food and Drug Administration

Neuren Pharmaceuticals Limited Commences Phase 2 Trials of NNZ-2591 in PMS and PTHS

Neuren Pharmaceuticals Limited Commences Phase 2 Trial of NNZ-2591 in Angelman

Neuren Pharmaceuticals Appoints Liza A. Squires as Chief Medical Officer in United States

Neuren Pharmaceuticals Limited Receives FDA Approval for Angelman IND and Phase 2 Trial

Neuren Pharmaceuticals Submits Investigational New Drug Application to the US Food and Drug Administration for NNZ-2591

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20.000001 million in funding

Neuren Pharmaceuticals Limited Submits an Investigational New Drug (IND) Application to the US Food and Drug Administration (FDA) for NNZ-2591 to Treat Angelman Syndrome

Neuren Pharmaceuticals Limited Receives Clear and Constructive Guidance from the Fda Office of Neuroscience in preIND Meetings for Phase 2 Clinical Trials of Nnz2591

Neuren Successfully Completes Drug Substance Manufacturing for NNZ-2591 Phase 2 Trials

Neuren Pharmaceuticals Limited Adds Prader-Willi Syndrome to Pipeline with Compelling Results for NNZ-2591 in Pre-Clinical Model

European Commission Grants 3 NNZ-2591 Orphan Designations to Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited Receives Approval for Final Stage of NNZ-2591 Clinical Trial

Neuren Pharmaceuticals Limited Initiates Manufacture of Nnz-2591 for Phase 2 Trials

Neuren Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.215561 million.

Neuren Pharmaceuticals Limited announced that it has received AUD 20.000012 million in funding

Neuren Pharmaceuticals Limited announced that it expects to receive AUD 20 million in funding

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies